Surfactants' Role in Nanovesicles Drug Delivery System | ||
| Records of Pharmaceutical and Biomedical Sciences | ||
| Volume 7, Issue 3, January 2023, Pages 140-149 PDF (636.32 K) | ||
| Document Type: Mini-reviews | ||
| DOI: 10.21608/rpbs.2023.219887.1238 | ||
| Authors | ||
| Shadeed Gad* 1; Pierre Hanna1; Hend Ibrahem2; Yasmin Mortagi2 | ||
| 1Faculty of Pharmacy - Suez Canal University | ||
| 2Department of Pharmaceutics, Faculty of Pharmacy, Sinai University, Arish 45511, Egypt | ||
| Abstract | ||
| Over the past few decades, the systemic delivery of numerous active compounds through buccal mucosa has increased significantly. A prolonged residency time provides for more medication penetration after mucoadhesion. Wafers have a higher drug load than cast films because of their porous construction. These mucoadhesive buccal dosage forms provide painless administration, direct access to the systemic circulation via the inner jugular vein, the ability to use permeation enhancers or pH modifiers in the established systems, avoidance of potential gastrointestinal enzyme degradation, and the possibility of therapy discontinuation. Edge activators (EAs) and non-ionic surfactants make up most of the elastic surfactant-based vesicles known as nanospanlastics—the deformable nanocarriers known as spanlastics were created by Kakkar and Kaur and are based on surfactants. Non-ionic surfactants and EAs constitute the majority of spanlastics. By squeezing through various pores of the biological layers without rupturing, EAs increase the flexibility and permeability of the vesicular membranes of nanocarriers, destabilizing them and increasing their flexibility and cross-membrane permeability. Inert, biodegradable, and safe deformable nanovesicles are called spanlastics. They also have more chemical stability than standard liposomes. | ||
| Keywords | ||
| solubility; nanovesicles; surfactants; spanlastics; drug delivery | ||
|
Statistics Article View: 338 PDF Download: 334 |
||
